The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies
Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.
An antibody, also known as an immunoglobulin, is a large Y-shaped protein produced by …..
This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.
July 2014 By Raveena Bhambra Q2 was full of deals, coupled with the talk of potential deals, and overall it finished on a high with a large volume of agreements coming together in June.
This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in June 2013
This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in May 2013
Analysis of data from the leading life science deals and alliances intelligence database Current Agreements and recently published Partnering Yearbook 2013 report series, shows that the top twenty partnering deals in the life sciences have a combined value of $20.6 billion
Sorry, your search returned no results.
Mersana Therapeutics have expanded their ongoing collaboration with Takeda Pharmaceutical to create novel Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology-relevant targets
ImmunoGen enters collaboration agreement with Eli Lilly and Company. Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel antibody-drug conjugate (ADC) anticancer therapeutics.
Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.